These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 31958711)
1. Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. Yao R; Wang H; Yuan M; Wang G; Wu C Psychiatry Res; 2020 Feb; 284():112750. PubMed ID: 31958711 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis. de Boer JN; Vingerhoets C; Hirdes M; McAlonan GM; Amelsvoort TV; Zinkstok JR Psychiatry Res; 2019 Aug; 278():294-302. PubMed ID: 31254879 [TBL] [Abstract][Full Text] [Related]
4. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836 [TBL] [Abstract][Full Text] [Related]
6. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028 [TBL] [Abstract][Full Text] [Related]
7. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. Salagre E; Fernandes BS; Dodd S; Brownstein DJ; Berk M J Affect Disord; 2016 Aug; 200():235-42. PubMed ID: 27148902 [TBL] [Abstract][Full Text] [Related]
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
9. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Owen RT Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
12. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Faridhosseini F; Sadeghi R; Farid L; Pourgholami M Hum Psychopharmacol; 2014 May; 29(3):216-23. PubMed ID: 24911574 [TBL] [Abstract][Full Text] [Related]
13. Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses. Lima TM; Visacri MB; Aguiar PM Eur J Clin Pharmacol; 2022 Mar; 78(3):311-338. PubMed ID: 34705064 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251 [TBL] [Abstract][Full Text] [Related]
15. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Crossley NA; Bauer M J Clin Psychiatry; 2007 Jun; 68(6):935-40. PubMed ID: 17592920 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of antidepressants in the treatment of adolescents and young adults with depression and substance use disorders: a systematic review and meta-analysis. Zhou X; Qin B; Del Giovane C; Pan J; Gentile S; Liu Y; Lan X; Yu J; Xie P Addiction; 2015 Jan; 110(1):38-48. PubMed ID: 25098732 [TBL] [Abstract][Full Text] [Related]
17. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Romeo B; Choucha W; Fossati P; Rotge JY Psychiatry Res; 2015 Dec; 230(2):682-8. PubMed ID: 26548981 [TBL] [Abstract][Full Text] [Related]